Does tamsulosin cause gynaecomastia? This is a question raised by men taking the alpha-blocker for benign prostatic hyperplasia (BPH) who notice unexpected breast changes. Tamsulosin is widely prescribed across the UK for lower urinary tract symptoms, and whilst gynaecomastia has been reported in post-marketing surveillance, there is no well-established direct causal link in the clinical literature. Understanding the evidence, recognising other contributing factors, and knowing when to seek medical advice are essential steps for anyone concerned about this potential side effect.

Tamsulosin and Gynaecomastia: What the Evidence Shows

Gynaecomastia has been reported with tamsulosin in post-marketing surveillance, but there is no well-established direct causal link; the frequency is not well defined and the mechanism is unclear.

Tamsulosin is an alpha-1 adrenoceptor blocker (alpha-blocker) widely prescribed in the UK for the management of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). It works by selectively relaxing smooth muscle in the prostate and bladder neck, improving urinary flow. Tamsulosin is uroselective and usually has minimal effect on blood pressure in normotensive men, though postural hypotension can still occur, particularly on standing.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — has been reported in association with tamsulosin. However, based on UK Summary of Product Characteristics (SmPC) documents available via the Electronic Medicines Compendium (eMC), gynaecomastia is typically recorded as a post-marketing adverse event with a frequency that is not well established. Patients and clinicians should check the SmPC for the specific brand prescribed, as frequency classifications may vary. The exact biological mechanism by which tamsulosin might contribute to gynaecomastia is not fully understood. Unlike some other medicines, tamsulosin does not directly alter sex hormone levels such as testosterone or oestrogen, which are the primary drivers of gynaecomastia in most clinical contexts.

It is important to note that there is no well-established, direct causal link between tamsulosin and gynaecomastia in the published clinical literature. The association arises from post-marketing surveillance data and case reports rather than large randomised controlled trials. Because this is based on spontaneous reporting, the true incidence is difficult to quantify precisely.

Patients who notice breast swelling or tenderness whilst taking tamsulosin should not automatically assume the medicine is responsible, as other causes are far more common. However, any new breast change in a male patient warrants proper clinical evaluation.

If you believe tamsulosin may have caused or contributed to a side effect, you can report this via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk). This helps regulators monitor the safety of medicines in real-world use.

How Common Is Gynaecomastia With Alpha-Blockers?

Gynaecomastia is not a prominent side effect across the alpha-blocker class; it is reported post-marketing with unknown frequency, far less commonly than retrograde ejaculation or dizziness.

Across the class of alpha-blockers — which includes tamsulosin, alfuzosin, doxazosin, and terazosin — gynaecomastia is not considered a prominent or frequently reported side effect. The more commonly recognised adverse effects of tamsulosin, as listed in the UK SmPC and NHS medicines information, include:

• Retrograde ejaculation (the most frequently reported sexual side effect)

• Dizziness or postural hypotension, particularly on standing

• Headache and rhinitis

• Palpitations (reported as uncommon, affecting fewer than 1 in 100 users)

Gynaecomastia, by contrast, has been reported post-marketing with a frequency that is not well established, meaning it is not expected to affect the majority of users. When compared with medicines that are strongly associated with gynaecomastia — such as spironolactone, cimetidine, anabolic steroids, or anti-androgens like bicalutamide — the risk with tamsulosin appears considerably lower.

It is also worth noting that BPH predominantly affects older men, a population in whom gynaecomastia may arise independently due to age-related hormonal shifts, increased body fat (which converts androgens to oestrogens via peripheral aromatisation), or comorbid conditions such as liver disease, thyroid dysfunction, or hypogonadism. This overlap makes it challenging to attribute gynaecomastia directly to tamsulosin in clinical practice.

Some men with BPH are also prescribed 5-alpha reductase inhibitors such as finasteride or dutasteride, either alone or in combination with tamsulosin. These medicines carry a more clearly established association with gynaecomastia and sexual side effects, and their concurrent use should always be considered when evaluating a patient presenting with breast changes.

Other Medicines and Factors That May Contribute

Drug-induced gynaecomastia has many recognised causes, including spironolactone, finasteride, and digoxin; underlying conditions such as hypogonadism, liver disease, and obesity must also be considered.

When a man taking tamsulosin develops gynaecomastia, it is essential to consider the full clinical picture before attributing the change to tamsulosin alone. A thorough medication review is a critical first step, as drug-induced gynaecomastia is recognised as a significant cause of the condition, involving a wide range of commonly prescribed medicines (NICE CKS: Gynaecomastia).

Medicines known to carry a higher risk of gynaecomastia include:

• Spironolactone (used in heart failure and hypertension)

• Finasteride and dutasteride (used in BPH and male pattern hair loss)

• Digoxin (used in atrial fibrillation and heart failure)

• Proton pump inhibitors such as omeprazole (associated in some case reports)

• Antipsychotics (via hyperprolactinaemia) and some antidepressants

• Anabolic steroids and testosterone therapy

• Calcium channel blockers such as amlodipine (rare association)

Beyond medication, several underlying health conditions can independently cause gynaecomastia. These include hypogonadism, hyperthyroidism, chronic liver disease, chronic kidney disease, and adrenal or testicular tumours. Obesity is also a significant contributing factor, as adipose tissue increases peripheral conversion of androgens to oestrogens. It is also important to distinguish true gynaecomastia (glandular tissue enlargement) from pseudogynaecomastia, which refers to breast enlargement due to adipose tissue alone and does not carry the same clinical implications.

Cannabis use and heavy alcohol consumption are recognised as potential contributing factors based on case reports and observational data; NHS guidance acknowledges these associations, though the evidence is variable in quality. A careful history should therefore explore recreational substance use alongside prescribed and over-the-counter medicines. Some herbal preparations — including topical lavender oil and tea tree oil — have been associated with gynaecomastia in case reports, predominantly involving prepubertal boys with topical exposure; evidence in adult men is very limited and these associations should be interpreted cautiously.

In summary, tamsulosin may be a contributing factor in rare cases, but clinicians and patients should approach gynaecomastia as a multifactorial finding requiring systematic evaluation rather than assuming a single cause.

When to Speak to Your GP or Pharmacist

Men should seek prompt GP assessment for any new breast lump or change; NICE NG12 recommends an urgent two-week referral if male breast cancer is suspected.

Any male who notices new or progressive breast swelling, tenderness, or a palpable lump whilst taking tamsulosin — or any other medicine — should seek a clinical assessment. Whilst gynaecomastia is usually benign, it is important to rule out male breast cancer, which, although rare, accounts for approximately 1% of all breast cancer diagnoses in the UK (NHS: Breast cancer in men).

You should contact your GP promptly if you notice:

• A firm, irregular, or eccentric lump (not centrally located beneath the nipple)

• Unilateral breast swelling that is rapidly enlarging

• Nipple discharge, skin changes, or nipple inversion

• Breast changes accompanied by unexplained weight loss, fatigue, or other systemic symptoms

• Breast tenderness that is significantly affecting your quality of life

Under NICE NG12 (Suspected cancer: recognition and referral), GPs should consider an urgent suspected cancer referral (within two weeks) for men aged 50 or over who present with a unilateral, firm subareolar mass with or without nipple changes. When cancer is suspected, assessment is usually carried out in a rapid-access breast clinic using triple assessment (clinical examination, imaging, and tissue sampling if required) rather than imaging arranged directly in primary care.

Your GP will typically take a full medical and medication history and examine the breast tissue. Blood tests may be arranged to assess hormone levels (including testosterone, LH, FSH, oestradiol, prolactin, and thyroid function), as well as liver and kidney function. Where a testicular or germ cell tumour is suspected, serum hCG (and AFP) should also be measured, and testicular examination with ultrasound considered (NICE CKS: Gynaecomastia).

If tamsulosin is suspected as a contributing cause, do not stop taking it without speaking to your GP or pharmacist first. Abruptly discontinuing tamsulosin can lead to a return of urinary symptoms, and the decision to switch or stop treatment should be made collaboratively. Your pharmacist can also provide an initial medication review and advise on whether any other medicines you are taking may be contributing to the breast changes.

Managing Side Effects While Continuing Treatment

Management options include watchful waiting, switching alpha-blocker, reviewing the full medication regimen, and addressing modifiable risk factors; specialist referral is appropriate for persistent or distressing gynaecomastia.

For most men, the urinary benefits of tamsulosin outweigh the rare risk of gynaecomastia, and many cases of mild breast changes may resolve spontaneously or with simple management strategies. The key principle is shared decision-making between the patient and their healthcare team, guided by the severity of symptoms and the availability of alternative treatments.

If tamsulosin is considered a likely contributor, your GP may consider the following options:

• Watchful waiting — monitoring mild, non-progressive gynaecomastia over time, particularly if it is not causing significant discomfort

• Switching to an alternative alpha-blocker — though evidence that other agents carry a meaningfully lower risk of gynaecomastia is limited

• Reviewing and adjusting the full medication regimen — removing or substituting other causative medicines where clinically appropriate

• Addressing modifiable risk factors — such as weight management, reducing alcohol intake, or stopping cannabis use

In cases where gynaecomastia is persistent, painful, or causing psychological distress, NICE CKS: Gynaecomastia supports referral to an endocrinologist or breast surgeon for further assessment. Medical treatments such as tamoxifen or raloxifene (selective oestrogen receptor modulators) have been used off-licence in some cases under specialist supervision; evidence for their use is limited and they are not routinely recommended in primary care.

Surgical correction (subcutaneous mastectomy) remains an option for longstanding or severe gynaecomastia that has not responded to other measures. However, NHS access to surgery varies by local Integrated Care Board (ICB) policy; procedures undertaken primarily for cosmetic reasons may not be funded, and individual funding requests or specific clinical criteria may apply. Your GP or specialist can advise on local referral pathways.

Throughout any management plan, maintaining open communication with your GP, pharmacist, and specialist team ensures that both your urinary health and overall wellbeing are appropriately supported. If you experience any suspected side effect from tamsulosin, you or your healthcare professional can report it via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions